Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Avita Medical Appoints Dr. Michael S. Perry to Board of Directors

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM -- (Marketwire) -- 02/06/13 -- Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY)

  • VP and Senior Global Program Head, Stem Cell Therapy at Novartis Pharmaceuticals
  • 25 Years Management Experience in Pharmaceutical and Biotech Development
  • Substantial Venture Capital Expertise in Life Science Funds

Regenerative medicine company Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY) today announced that Dr. Michael S. Perry, Vice President and Senior Global Program Head, Stem Cell Therapy at Novartis Pharmaceuticals Corp., has been appointed to the company's board of directors. Dr. Perry has over 25 years of successful pharmaceutical/biotech management and development experience.

Dalton Gooding, Avita Medical chairman, said, "Michael has extraordinary biotech and business expertise, and we are delighted that he is joining Avita's board of directors."

Perry currently serves as Vice President and Senior Global Program Head, Stem Cell Therapy at Novartis Pharmaceuticals Corp, a US affiliate of Switzerland-based Novartis AG, a world leader in the research and development of products to protect and improve health and well-being with core businesses in pharmaceuticals, vaccines, consumer health, generics, eye care and animal health.

Dr. Perry, based in the United States, has previously served as the Global Head of R&D at Baxter Healthcare, President, Cell & Gene Therapy at Novartis affiliates SyStemix and Genetic Therapy, Inc., VP Regulatory Affairs at Sandoz Pharmaceuticals Corp., Director of Regulatory Affairs at Schering-Plough Corporation, and Chairman, CEO or CMO at several early stage biotech companies.

From 2005 to 2012, Dr. Perry was a Venture Partner with Bay City Capital, a California-based venture capital firm managing over US$1.6 billion invested predominantly in life science companies.

"Michael brings a wealth of experience and scientific acumen as well as the insights that come from running successful large global divisions and emerging startups. Michael will be a great addition to our board and I am delighted to be working with him," said Dr William Dolphin, Avita chief executive officer.

"I am honoured to join the Avita board and work with this exceptional team," Perry said. "Avita has the potential to make a significant impact in the field of regenerative medicine and I look forward to sharing my experiences and contributing to the future direction and growth at this early stage in the company's history."

In addition to Avita Medical, Dr. Perry currently serves on the board of two publicly held companies.

ABOUT AVITA MEDICAL LTD.
Avita Medical (http://www.avitamedical.com/) develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell® Spray-On Skin™, is used in a wide variety of burns, chronic wounds, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the US ReCell is an investigational device limited by federal law to investigational use. An FDA trial on the safety and efficacy of ReCell is in process.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Avita Medical Ltd.
Stella Sung, Ph.D.
Business Development Officer
Phone: +1 838-352-9400
Email: ssung@avitamedical.com

Investor Relations:
ProActive Capital Resources Group, LLC
Jeff Ramson
CEO
641 Lexington Avenue, 6th Floor
New York, NY. 10022
Phone: +1 646-863-6893
Email: jramson@proactivecapitalgroup.com

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Cloud Developer Stories
Sony and Electrolux have joined the AllSeen Alliance, an open-source interoperability project for the IoT being led by Microsoft and also including Haier, LG, Panasonic, Qualcomm, Sharp, Silicon Image, Technicolor and TP-Link . There dozens of other community members in the proje...
SYS-CON Events announced today that TechXtend (formerly Programmer’s Paradise), a leading value-added provider of server and storage virtualization, and r-evolution will exhibit at SYS-CON's 15th International Cloud Expo®, which will take place on November 4–6, 2014, at the Santa...
The consumption economy is here and so are cloud applications and solutions that offer more than subscription and flat fee models and at the same time are available on a pure consumption model, which not only reduces IT spend but also lowers infrastructure costs, and offers ease ...
Every healthy ecosystem is diverse. This is especially true in cloud ecosystems, where portability and interoperability are more important than old enterprise models of proprietary ownership. In his session at 15th Cloud Expo, Mark Baker, Server Product Manager at Canonical/Ubunt...
SYS-CON Events announced today that Cloudian, Inc., the leading provider of hybrid cloud storage solutions, has been named “Bronze Sponsor” of SYS-CON's 15th International Cloud Expo®, which will take place on November 4–6, 2014, at the Santa Clara Convention Center in Santa Clar...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE

Breaking Cloud Computing News

-- The deadline for submitting your Speaker Proposal -- 30th September 2014.